Brought to you by 
GSK sells non-ophthalmic Zovirax rights to Valeant for $300mm
05 Feb 2013
Executive Summary
Valeant Pharmaceuticals International Inc.’s Biovail Laboratories International SRL has paid $300mm in cash for US and Canadian rights to GlaxoSmithKline PLC’s Zovirax (acyclovir) ointment and cream for topical use for all indications except ophthalmology. Zovirax is marketed for herpes infections and had 2010 worldwide sales of £152mm ($235mm).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK sells non-ophthalmic Zovirax rights to Valeant for $300mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice